Catalyst
Pit
Terminal
Pit Consensus
Insiders
Politicians
Institutions
News
Screener
More ▾
Terminal
Pit Consensus
Insiders
Politicians
Institutions
News
Screener
More ▾
☰
NAMS
NewAmsterdam Pharma Co N.V.
NASDAQ · Pharmaceutical Preparations
Last close
$24.32
· 2026-09-30
ABOUT
Exchange
NASDAQ
Sector
Healthcare
Industry
Pharmaceutical Preparations
RECENT INSIDER TRADES
2026-10-02
· Kastelein Johannes Jacob Pieter
(Chief Scientific Officer)
· OTHER
2026-10-02
· Kastelein Johannes Jacob Pieter
(Chief Scientific Officer)
· SELL
2026-09-15
· Davidson Michael H.
(Chief Executive Officer)
· BUY
2026-09-09
· Smither John W
(Director)
· SELL
2026-08-25
· Kastelein Johannes Jacob Pieter
(Chief Scientific Officer)
· SELL
INSTITUTIONAL OWNERSHIP
Institutional holders
204
Shares held
121,827,810
Value
$4.03B
Percent of shares outstanding
101.92%
As of quarter end
2026-06-30
RECENT NEWS
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease
NewAmsterdam Pharma (NAMS) Wins EU Approvals. Can Cholesterol Pills Drive Royalties?
Menarini Group and NewAmsterdam Pharma Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco®
NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco®
Catalyst
Pit
Features
Coming soon
Pricing
Coming soon
Privacy
Terms
Disclaimer
Affiliate Terms
Contact
2026 CATALYSTPIT · NOT FINANCIAL ADVICE · DELAYED FILINGS